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Abstract: 
Introduction: Among the new options against H pylori brought to light recently, azithromycin has attracted 
substantial interest. Clinical trials with triple therapy regimens that contain azithromycin have reported eradication 
rates of approximately 60%-80%, depending on the regimen and azithromycin dose used. 
Objective: To compare the efficacy of triple therapies for H. pylori eradication with verses without Azithromycin in 
patients with active duodenal ulcer 
Setting: Department of Medicine, Jinnah Post Graduate and Medical Centre, Karachi. 
Study Design: Randomized controlled Trial  
Duration of Study: Six months started on December 14, 2013 to June 13, 2014 
Subjects and Methods: All patients of either gender with age 30-60 years presented with active duodenal ulcer with 
H Pylori and duration of symptoms more than 3 months were enrolled. Group A was prescribed Azithromycin 1 g 
OD for the first 3 days (total dose 3 g), amoxicillin 1 g bid and omeprazole 20 mg bid (OAA).  Group B 
metronidazole 500 mg bid, amoxicillin 1 g bid and omeprazole 20 mg bid (OAM). Both the therapy was given for 1 
week, followed by monotherapy of Omeprazole 20 mg OD in both groups for 3 weeks. At the end of the 8th week 
endoscopy and urea breath test was performed.Results: Mean age of the patients was 44.06 ±8.70 years. Mean 
duration of symptoms of the patients was 5.91 ±1.36 months. Male preponderance was found to be higher 35 
(58.30%) as compared to female 24 (40%). In patients presented in OAA triple therapy group, efficacy was found in 
19 (63.3%) patients whereas, in patients presented in OAM triple therapy group, efficacy was found in 8 (26.7%) 
patients (p-value 0.004). 
Conclusion: The efficacy of triple therapies for H. pylori eradication with Azithromycin is more versus without 
Azithromycin in patients with active duodenal ulcer 
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INTRODUCTION: 
Infection caused by Helicobacter pylori (H pylori), 
one of the most common pathogens worldwide, 
causes chronic gastritis and increases the risk of 
peptic ulcer and gastric cancer. Although some H 
pylori-positive individuals are asymptomatic, many 
experience symptoms such as dyspepsia. It is 
increasingly common to screen patients, even those 
with mild symptoms, for H pylori infection, and to 
treat them actively. The first-line treatment for H 
pylori infection, as recommended by the Maastricht 
III Consensus Report, is 7-d triple therapy that 
includes clarithromycin, amoxicillin and a proton-
pump inhibitor (PPI). Even though this triple therapy 
is effective and its short duration helps maintain 
patient compliance, a considerable number of patients 
experience undesirable side effects. 
 
In first-line therapy, eradication rates using 
combinations of PPI-based triple therapies range 
from 75% to 98%, with most of them near 80%.2 This 
signifies that up to 20% of patients are expected to be 
treatment failures, a value which could be even 
higher in areas with a high prevalence of resistant H 
pylori strains. The recommended second-line therapy 
is a quadruple regimen composed of tetracycline, 
metronidazole, bismuth salts and a PPI; however, the 
efficacy of this regimen is limited by poor 
compliance, treatment duration, number and dose of 
the prescribed drugs, and bacterial antibiotic 
resistance. 
 
Among the new options against H pylori brought to 
light recently, azithromycin has attracted substantial 
interest. Azithromycin is a macrolide antibiotic that 
has been shown to reach high concentrations in 
gastric tissue after oral administration; furthermore, 
these high concentrations are maintained for several 
days, which make it potentially useful in the 
eradication of H pylori. Clinical trials with triple 
therapy regimens that contain azithromycin have 
reported eradication rates of approximately 60%-
80%, depending on the regimen and azithromycin 
dose used.  
 
H. pylori infection was eradicated in 15 out of 50 
patients with OAM: eradication rate was 30.6 % (95 
% CI: 17.6 %- 43.6 %) Per Protocols and 30 % (95% 
CI: 17-43 %) Intension to treat analysis. H. pylori 
infection was eradicated in 36 out of 50 patients 
treated with OAA: eradication rate was 75% (95 % 
CI: 63-87 %) Per Protocols and 72 % (95 % CI: 59-
85 %) - Intension to treat analysis. H. pylori status 
was assessed by rapid urease test and histology. The 
strong association between H. pylori infection and 
peptic ulcer disease is unarguable. Meta-analysis 
studies have showed superior ulcer remission rate for 
both gastric and duodenal ulcers in patients 
successfully eradicated of H. pylori infection.  
 
H. pylori eradication therapy was also more superior 
and cost-effective than maintenance acid suppressive 
therapy in preventing duodenal ulcer. Azithromycin 
has been used in various combinations and studies 
shows no difference in different combinations as the 
p value found to be more than the significance level. 
In a Randomized Controlled Trial: Efﬁcacy and 
Safety of Azithromycin, Oﬂoxacin, Bismuth, and 
Omeprazole Compared with Amoxicillin, 
Clarithromycin, Bismuth, and Omeprazole as 
Second-Line Therapy in Patients with Helicobacter 
pylori Infection in intention-to-treat analysis, the rate 
of H. pylori eradication in groups A (Azithromycin) 
and B was 77.3% (85 ⁄ 110) and 64.5% (71 ⁄ 110) 
respectively (p = 0.027).  H. pylori was eradicated in 
86% of patients in the early group (intention-to-treat 
86%) and in 88% of patients in the late group 
(intention-to-treat 88%). There is variation in the 
outcome of azithromycin in the treatment of H Pylori 
infection, therefore the present study is designed to 
resolve the issue. In the event of higher efficacy in 
the either triple regime the same was used in such 
cases in future. 
 
MATERIAL AND METHODS: 
The design of the study is randomized controlled trial 
study conducted in the Department of Medicine, 
Jinnah Post Graduate and Medical Centre, Karachi. 
And the duration of this study was Six months started 
on December 14, 2013 to June 13, 2014. Considering 
the cost and easy availability of triple regimen 
combination of OAA and OAM, the sample size 
calculated on WHO calculator using the reference no. 
6, which is relevant to our hypothesis on the basis of 
following prerequisites: 
 
 Efficacy of OAA triple therapy6=75% 
Efficacy of OAM triple therapy6=30.6%%  
Power of the test=80% 
Significance level=5% 
Total sample size=30 patients but we will 
take 60 patients (30 in each group) to have 
more valid results.  
 
Patients meeting the inclusion criteria attending the 
outpatient Department of JPMC Karachi, was 
enrolled in the study. Informed consent was taken 
from the patients for inclusion in the study and for 
procedure after explaining the pros and cons, purpose 
and procedure of the study. Randomization was 
performed by making equal draws and draw was 
picked up by third person not related to this study 
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into two groups A and B. Group A were prescribed 
Azithromycin 1 g OD for the first 3 days (total dose 3 
g), amoxicillin 1 g bid and omeprazole 20 mg bid 
(OAA).  Group B metronidazole 500 mg bid, 
amoxicillin 1 g bid and omeprazole 20mg bid 
(OAM). Both the therapy was given for 1 week, 
followed by monotherapy of Omeprazole 20 mg OD 
in both groups for 3 weeks. At the end of the 8th week 
endoscopy and urea breath test was performed by 
gastroenterologist having more than 5 years of 
experience for eradication of H Pylori. This 
information as well as demographic data like patients 
age, sex, duration of symptoms was documented on 
structured Performa. SPSS version 20 was used for 
data entry and analysis. Mean±SD was calculated for 
age of the patients, duration of symptoms. Frequency 
and percentages was calculated for gender and 
efficacy. Chi square test was applied to test the 
hypothesis. Effect modifiers were controlled through 
stratification of age, gender, and duration of 
symptoms to determine the effect of these on 
outcome. Chi square test was applied and p value 
≤0.05 was taken as significant.      
 
RESULTS: 
Mean age of the patients was 44.06 ±8.70 years. The 
minimum age of the patients was 30 years and 
maximum age of the patients was 60 years. (Table 1). 
There were 34 (56.70%) patients with age ≤45 years 
and 26 (43.30%) patients with age >45 years. (Figure 
1). Mean duration of symptoms of the patients was 
5.91 ±1.36 months. The minimum duration of 
symptoms was 4 and maximum duration of 
symptoms was 8 months. (Table 2). There were 32 
(53.30%) patients with duration of symptoms ≤6 
months and 28 (46.70%) patients with duration of 
symptoms >6 months. (Figure 2). Male 
preponderance was found to be higher 35 (58.30%) 
as compared to female 24 (40%). (Figure 3). Overall 
efficacy was found in 27 (45%) patients. (Figure 4).  
 
In patients presented in OAA triple therapy group, 
efficacy was found in 19 (63.3%) patients whereas, in 
patients presented in OAM triple therapy group, 
efficacy was found in 8 (26.7%) patients. Chi-square 
test was applied and statistically sufficient evidence 
of significant relationship was observed as p-value 
found to be less than level of significance (p-value 
0.004). (Table 3). Stratification was done to see the 
effect of age, duration of disease and gender. Chi-
square test was applied. Results are shown in table 3-
9.  
 
Table 1: Age of the Patients (n=60) 
 
 
 
 
 
 
Mean ±SD Minimum Maximum 
44.06 ±8.70 30 60 
0.00%
10.00%
20.00%
30.00%
40.00%
50.00%
60.00%
≤45 >45
34 (56.70%)
26 (43.30%)
Figure 1: Age Groups
≤45 >45
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Table 2: Duration of Symptoms (n=60) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3: Efficacy with Respect to Group (n=60) 
Group 
Efficacy 
Total p-value 
Yes No 
OAA triple therapy 19 (63.3) 11 (36.7) 30 (100) 
0.004 OAM triple therapy 8 (26.7) 22 (73.3) 30 (100) 
Total 27 (45%) 33 (55%) 60 (100) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4: Age ≤45 Years & Efficacy with Respect to Group (n=34) 
Group 
Efficacy 
Total p-value 
Yes No 
OAA triple therapy 9 (56.3) 7 (43.8) 16 (100) 
0.092 OAM triple therapy 5 (27.8) 13 (72.2) 18 (100) 
Total 14 (41.2) 20 (58.8) 34 (100) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mean ±SD Minimum Maximum 
5.91 ±1.36 4 8 
40.00%
50.00%
60.00%
≤6 >6
32 (53.30%)
28 (46.70%)
Figure 2: Duration of symptoms
≤6 >6
Male,             
35 
(58.30%)
Female,         
24 (40%)
Figure 3: Gender Distribution
0%
100%
Yes No
27 (45%) 33 (55%)
Figure 4: Overall Efficacy
Yes No
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Table 5: Age >45 Years & Efficacy with Respect to Group (n=26) 
Group 
Efficacy 
Total p-value 
Yes No 
OAA triple therapy 10 (71.4) 4 (28.6) 14 (100) 
0.018 OAM triple therapy 3 (25) 9 (75) 12 (100) 
Total 13 (50%) 13 (50%) 26 (100) 
 
Table 6: Duration of Diseases ≤6 Months & Efficacy with Respect to Group (n=32) 
Group 
Efficacy 
Total p-value 
Yes No 
OAA triple therapy 19 (79.2) 5 (20.8) 24 (100) 
0.001 OAM triple therapy 0 (0) 8 (100) 8 (100) 
Total 19 (59.4) 13 (40.6%) 32 (100) 
 
Table 7: Duration of Diseases >6 Months & Efficacy with Respect to Group (n=28) 
Group 
Efficacy 
Total p-value 
Yes No 
OAA triple therapy 0 (0) 6 (100) 6 (100) 
0.081 OAM triple therapy 8 (36.4) 14 (63.6) 22 (100) 
Total 8 (28.6) 20 (71.4) 28 (100) 
 
Table 8: Male Gender & Efficacy with Respect to Group (n=35) 
Group 
Efficacy 
Total p-value 
Yes No 
OAA triple therapy 14 (73.7) 5 (26.3) 19 (100) 
0.004 OAM triple therapy 4 (25) 12 (75) 16 (100) 
Total 18 (51.4) 17 (48.6) 35 (100) 
 
Table 9: Female Gender & Efficacy with Respect to Group (n=25) 
Group 
Efficacy 
Total p-value 
Yes No 
OAA triple therapy 5 (45.5) 6 (54.5) 11 (100) 
0.558 OAM triple therapy 4 (28.6) 10 (71.4) 14 (100) 
Total 9 (36) 16 (64) 25 (100) 
 
DISCUSSION: 
Azithromycin is a macrolide antibiotic that has been 
shown to reach high concentrations in gastric tissue 
after oral administration; furthermore, these high 
concentrations are maintained for several days, which 
make it potentially useful in the eradication of H 
pylori. Clinical trials with triple therapy regimens that 
contain azithromycin have reported eradication rates 
of approximately 60%-80%, depending on the regimen 
and azithromycin dose used. Results of present study 
shows that, in patients presented in OAA triple therapy 
group, efficacy was found in 19 (63.3%) patients 
whereas, in patients presented in OAM triple therapy 
group, efficacy was found in 8 (26.7%) patients (p-
value 0.004). H. pylori infection was eradicated in 15 
out of 50 patients with OAM: eradication rate was 
30.6 % (95 % CI: 17.6 %- 43.6 %) Per Protocols and 
30 % (95% CI: 17-43 %) Intension to treat analysis. H. 
pylori infection was eradicated in 36 out of 50 patients 
treated with OAA: eradication rate was 75% (95 % CI: 
63-87 %) Per Protocols and 72 % (95 % CI: 59-85 %)-
Intension to treat analysis. H. pylori status was 
assessed by rapid urease test and histology.  
 
The strong association between H. pylori infection and 
peptic ulcer disease is unarguable. Meta-analysis 
studies have showed superior ulcer remission rate for 
both gastric and duodenal ulcers in patients 
successfully eradicated of H. pylori infection. H. 
pylori eradication therapy was also more superior and 
cost-effective than maintenance acid suppressive 
therapy in preventing duodenal ulcer. Azithromycin 
has been used in various combinations and studies 
shows no difference in different combinations as the p 
value found to be more than the significance level. In a 
Randomized Controlled Trial: Efﬁcacy and Safety of 
Azithromycin, Oﬂoxacin, Bismuth, and Omeprazole 
Compared with Amoxicillin, Clarithromycin, Bismuth, 
and Omeprazole as Second-Line Therapy in Patients 
with Helicobacter pylori Infection. In intention-to-treat 
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analysis, the rate of H. pylori eradication in groups A 
(Azithromycin) and B was 77.3% (85 ⁄ 110) and 
64.5% (71 ⁄ 110) respectively (p = 0.027). H. pylori 
was eradicated in 86% of patients in the early group 
(intention-to-treat 86%) and in 88% of patients in the 
late group (intention-to-treat 88%). Infection caused 
by Helicobacter pylori (H pylori), one of the most 
common pathogens worldwide, causes chronic 
gastritis and increases the risk of peptic ulcer and 
gastric cancer. Although some H pylori-positive 
individuals are asymptomatic, many experience 
symptoms such as dyspepsia. It is increasingly 
common to screen patients, even those with mild 
symptoms, for H pylori infection, and to treat them 
actively. The first-line treatment for H pylori infection, 
as recommended by the Maastricht III Consensus 
Report, is 7-d triple therapy that includes 
clarithromycin, amoxicillin and a proton-pump 
inhibitor (PPI). Even though this triple therapy is 
effective and its short duration helps maintain patient 
compliance, a considerable number of patients 
experience undesirable side effects. 
 
In first-line therapy, eradication rates using 
combinations of PPI-based triple therapies range from 
75% to 98%, with most of them near 80%. This 
signifies that up to 20% of patients are expected to be 
treatment failures, a value which could be even higher 
in areas with a high prevalence of resistant H 
pylori strains. The recommended second-line therapy 
is a quadruple regimen composed of tetracycline, 
metronidazole, bismuth salts and a PPI; however, the 
efficacy of this regimen is limited by poor compliance, 
treatment duration, number and dose of the prescribed 
drugs, and bacterial antibiotic resistance. From 1995 to 
the present, numerous clinical study results specific to 
H. pylori eradication triple therapy with pantoprazole 
have been published. 
 
Most of these studies have shown consistent success 
using triple-therapy regimens with durations shorter 
than 14 days (some ≤ 10 days). Many of these studies 
were conducted outside the United States, where 
resistance patterns may be different. Pilotto et al. 
recently reported an H. Pylori eradication rate of 94% 
with a triple therapy consisting of 40 mg pantoprazole, 
1000 mg amoxicillin, and 250 mg clarithromycin daily 
for 7 days among elderly patients with peptic ulcer 
disease in Vicenza, Italy. Other analyses have 
compared pantoprazole-based combination peptic 
ulcer disease therapies with others using omeprazole, 
lansoprazole or Multidrug Regimens and 
Recommendations The addition of a proton pump 
inhibitor (PPI) to antibiotic-containing regimens has 
generally been demonstrated to boost H. pylori 
eradication rates. 
CONCLUSION: 
The efficacy of triple therapies for H. pylori 
eradication with Azithromycin is more versus without 
Azithromycin in patients with active duodenal ulcer. 
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